AUTHOR=Liu Yanchao , Zhang Shujuan , He Benrong , Chen Liangkai , Ke Dan , Zhao Shi , Zhang Yao , Wei Wei , Xu Zhipeng , Xu Zihui , Yin Ying , Mo Wen , Li Yanni , Gao Yang , Li Shihong , Wang Weijin , Yu Huiling , Wu Dongqin , Pi Guilin , Jiang Tao , Deng Mingmin , Xiong Rui , Lei Huiyang , Tian Na , He Ting , Sun Fei , Zhou Qiuzhi , Wang Xin , Ye Jinwang , Li Mengzhu , Hu Nan , Song Guoda , Peng Wenju , Zheng Chenghong , Zhang Huaqiu , Wang Jian-Zhi 

TITLE=Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=9

YEAR=2021

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.752753

DOI=10.3389/fcell.2021.752753

ISSN=2296-634X

ABSTRACT=<p><bold>Introduction:</bold> Type 2 diabetes mellitus (T2DM) is an independent risk factor of Alzheimer’s disease (AD), and populations with mild cognitive impairment (MCI) have high incidence to suffer from AD. Therefore, discerning who may be more vulnerable to MCI, among the increasing T2DM populations, is important for early intervention and eventually decreasing the prevalence rate of AD. This study was to explore whether the change of plasma β-amyloid (Aβ) could be a biomarker to distinguish MCI (T2DM-MCI) from non-MCI (T2DM-nMCI) in T2DM patients.</p><p><bold>Methods:</bold> Eight hundred fifty-two T2DM patients collected from five medical centers were assigned randomly to training and validation cohorts. Plasma Aβ, platelet glycogen synthase kinase-3β (GSK-3β), apolipoprotein E (ApoE) genotypes, and olfactory and cognitive functions were measured by ELISA, dot blot, RT-PCR, Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test based on the diluted butanol, and Minimum Mental State Examination (MMSE) test, respectively, and multivariate logistic regression analyses were applied.</p><p><bold>Results:</bold> Elevation of plasma Aβ1-42/Aβ1-40 is an independent risk factor of MCI in T2DM patients. Although using Aβ1-42/Aβ1-40 alone only reached an AUC of 0.631 for MCI diagnosis, addition of the elevated Aβ1-42/Aβ1-40 to our previous model (i.e., activated platelet GSK-3β, ApoE ε4 genotype, olfactory decline, and aging) significantly increased the discriminating efficiency of T2DM-MCI from T2DM-nMCI, with an AUC of 0.846 (95% CI: 0.794–0.897) to 0.869 (95% CI: 0.822–0.916) in the training cohort and an AUC of 0.848 (95% CI: 0.815–0.882) to 0.867 (95% CI: 0.835–0.899) in the validation cohort, respectively.</p><p><bold>Conclusion:</bold> A combination of the elevated plasma Aβ1-42/Aβ1-40 with activated platelet GSK-3β, ApoE ε4 genotype, olfactory decline, and aging could efficiently diagnose MCI in T2DM patients. Further longitudinal studies may consummate the model for early prediction of AD.</p>